← Back

Anavex Life Sciences Corp

Anavex Life Sciences Corp. is a biopharmaceutical company developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental and neurodegenerative disorders, rare diseases including Rett syndrome, other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 trial in Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and a Phase 2 and a Phase 3 study in adults plus one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX 2-73 is an orally available candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, and it showed anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models. The company's ANAVEX 3-71 targets SIGMAR1 and M1 muscarinic receptors and is a clinical-stage candidate showing disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

Price · split & dividend adjusted
News & notes moving 0HFR.LSE
0HFR.LSE▼

Glass Lewis Backs Two PVG Nominees for Anavex Board

Proxy advisory firm Glass Lewis said Anavex Life Sciences shareholders should vote for two of PVG Asset Management's director nominees, Curtis Hogue and Jason Kolbert, while advising against incumbent Chairman Jiong Ma and incumbent director Claus van der Velden. In its report, Glass Lewis recommended replacing Ma and van der Velden in favor of novel candidates with more relevant expertise, fresh perspectives and, critically, no evident responsibility for the circumstances giving rise to Anavex's strategic missteps, regulatory headwinds, dubious governance architecture and substantial trading declines. PVG Asset Management President Patrick S. Adams said stockholders should insist that this board finally have skin in the game and elect all six PVG nominees, who are committed to requiring meaningful stock ownership for all directors and officers as part of the plan to restore and maximize shareholder value. PVG's other four nominees are Adams, John Boris, Rene Mora, and Ralf von Ziegesar. Institutional Shareholder Services, another proxy advisory firm, recently advised voting for Anavex's proposed slate of six nominees.
AVXL ▼
Seeking Alpha·1dRead more →
0HFR.LSE

Anavex Rises as PVG Pushes Board Reshuffle

Anavex Life Sciences traded higher in the premarket on Friday after PVG Asset Management urged shareholders to vote for its six board nominees at the annual meeting on September 24. PVG, which owns roughly 327,300 shares, criticized the current board for lacking biotech experience and holding only 5,000 shares collectively. The company had previously nominated Gautam Patel and Adrian Senderowicz as new independent directors, replacing ex-CEO Christopher Missling and director Steffen Thomas. PVG argues its nominees bring significant biotech expertise and a stronger stake in the company's performance.
AVXL
Seeking Alpha·14dRead more →
Biotech & Genomic Medicine▲

Anavex Advances Alzheimer's Phase 3 Planning as Cash Runway Extends Into Fiscal 2028

Anavex Life Sciences is advancing Alzheimer's Phase 3 planning with the FDA after submitting its clinical trial data to a newly opened Alzheimer's IND, while reporting $118.3 million in cash and an expected operating runway into mid to late fiscal 2028. The company ended June with $118.3 million in cash and cash equivalents, up from $102.6 million at September 2025 fiscal year-end, and management expects existing cash to fund operations into mid to late fiscal 2028. Anavex has submitted all Alzheimer's clinical trial data to its new IND and plans further FDA discussions covering its U.S. clinical development programme and proposed ANAVEX2-73-AD-005 Phase 3 trial, having received scientific advice from the EMA in June on study population, endpoint hierarchy, treatment duration, statistical framework and subgroup strategy. The company is moving ahead with an approximately 170-participant adult Phase 3 Rett syndrome study and has requested an FDA meeting about adding paediatric patients, while a Fragile X syndrome IND is expected to be submitted in September. Anavex reported third-quarter net income of $7.8 million, or $0.08 per share, compared with a $13.2 million loss, or $0.16 per share, a year earlier, though the improvement was primarily driven by reversals of stock-based compensation associated with employee terminations, including the former CEO.
AVXL ▲
Biotech & Genomic Medicine
Yahoo Finance·24dRead more →
© 2026 MarketDXAsset